Reprounion

Reproductive challenges currently affect 16-25% of all couples in the Nordics. Every 5th man never becomes a father, and every 10th woman has no or fewer children than she had hoped for. Infertility has been recognized as a disease by the WHO, but despite revolutionary developments in the techniques for assisted reproduction, the success rate per treatment, is still below 30%. ReproUnion is a cross-border collaboration between Sweden and Denmark within the area of reproductive medicine in the Øresund Region. During 15 years, the ReproUnion partnership has been collaborating across disciplines between academia, hospitals, and industry with more than 50 professors and researches involved. Our aim is to understand the underlying reasons of infertility and to personalise and improve reproductive treatment. To do so, ReproUnion is building an innovation platform to help the industry gain access to cutting-edge expertise and research infrastructure. This entrepreneurial setting is also inspiring the utilization of public research in patents and future spin-outs. The core of the Innovation platform is the ReproUnion Biobank & Infertility Cohort (RUBIC) and other testbed facilities that can be used to streamline commercialization pathways with the ultimate goal of creating tangible benefits for patients. This includes resources that can be used to develop, test, and validate novel solutions within reproductive health area. Public-private partnerships like ReproUnion are an important part of the solution to the challenges facing our healthcare systems. It´s about innovation and growth, but first and foremost it´s about putting patients´ needs first! ReproUnion is funded by EU Interreg Interreg Öresund-Kattegat-Skagerrak, the Capital Region of Denmark, Region Skåne and Ferring Pharmaceuticals.